Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2021 Jan 1;50(1):54-63.
doi: 10.1097/MPA.0000000000001722.

A 3-Decade Analysis of Pancreatic Adenocarcinoma After Solid Organ Transplant

Juan E Corral  1 , Kristopher P Croome  2 , Andrew P Keaveny, Bhaumik Brahmbhatt  1 , Paul T Kröner  1 , Karn Wijarnpreecha  1 , Rohan M Goswami  2 , Massimo Raimondo  1 , Michael B Wallace  1 , Yan Bi  1 , Omar Y Mousa
Affiliations
Multicenter Study

A 3-Decade Analysis of Pancreatic Adenocarcinoma After Solid Organ Transplant

Juan E Corral et al. Pancreas. .

Erratum in

Abstract

Objective: Solid organ transplant (SOT) recipients have moderately increased risk of pancreatic adenocarcinoma (PAC). We evaluated the incidence and survival of PAC in 2 cohorts and aimed to identify potential risk factors.

Methods: This study performed a retrospective cohort analysis. Cohort A was extracted from the United Network of Organ Sharing data set and cohort B from SOT recipients evaluated at 3 Mayo Clinic transplant centers. The primary outcome was age-adjusted annual incidence of PAC. Descriptive statistics, hazard ratios, and survival rates were compared.

Results: Cohort A and cohort B included 617,042 and 29,472 SOT recipients, respectively. In cohort A, the annual incidence rate was 12.78 per 100,000 in kidney-pancreas, 13.34 in liver, and 21.87 in heart-lung transplant recipients. Receiving heart-lung transplant, 50 years or older, and history of cancer (in either recipient or donor) were independent factors associated with PAC. Fifty-two patients developed PAC in cohort B. Despite earlier diagnosis (21.15% with stage I-II), survival rates were similar to those reported for sporadic (non-SOT) patients.

Conclusions: We report demographic and clinical risk factors for PAC after SOT, many of which were present before transplant and are common to sporadic pancreatic cancer. Despite the diagnosis at earlier stages, PAC in SOT portends a very poor survival.

PubMed Disclaimer

Conflict of interest statement

J.E.C. received a travel grant from Abbvie, Inc, and minor food and beverage from Boston Scientific and Cook Medical. M.B.W. is a consultant at Virgo, Inc, Cosmo/Aries Pharmaceuticals, Anx Robotica (2019), and Covidien; received research grants from Fujifilm, Boston Scientific, Olympus, Medtronic, Ninepoint Medical, and Cosmo/Aries Pharmaceuticals; and received stock/stock options from Virgo, Inc. M.B.W. does consulting on behalf of Mayo Clinic: GI Supply (2018), EndoKey, Endostart, and Boston Scientific and received minor food and beverage from Synergy Pharmaceuticals, Boston Scientific, and Cook Medical. The other authors declare no conflict of interests.

References

    1. Engels EA, Pfeiffer RM, Fraumeni JF Jr, et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA . 2011;306:1891–1901.
    1. Vajdic CM, van Leeuwen MT. Cancer incidence and risk factors after solid organ transplantation. Int J Cancer . 2009;125:1747–1754.
    1. Adami J, Gäbel H, Lindelöf B, et al. Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer . 2003;89:1221–1227.
    1. Collett D, Mumford L, Banner NR, et al. Comparison of the incidence of malignancy in recipients of different types of organ: a UK Registry audit. Am J Transplant . 2010;10:1889–1896.
    1. Hoffmann CJ, Subramanian AK, Cameron AM, et al. Incidence and risk factors for hepatocellular carcinoma after solid organ transplantation. Transplantation . 2008;86:784–790.

Publication types

MeSH terms

LinkOut - more resources